Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum

Pharmacokinetics of meglumine antimoniate in dogs with experimentally induced leishmaniosis has been investigated. After infection, dogs received a dose of 75 mg kg −1 of meglumine antimoniate twice daily by subcutaneous injection for 10 days. Blood samples were collected throughout the treatment. N...

Full description

Saved in:
Bibliographic Details
Published in:Veterinary parasitology 1998-02, Vol.75 (1), p.33-40
Main Authors: Valladares, Josep-Enric, Riera, Cristina, Alberola, Jordi, Gállego, Montserrat, Portús, Montserrat, Cristòfol, Carles, Franquelo, Carme, Arboix, Margarita
Format: Article
Language:English
Subjects:
Analysis of Variance
Animals
Antibodies, Protozoan - blood
Antiprotozoal Agents - administration & dosage
Antiprotozoal Agents - pharmacokinetics
Antiprotozoal Agents - therapeutic use
Control methods—Protozoa
Dog
Dog Diseases
Dogs
Drug Administration Schedule
Injections, Subcutaneous
Leishmania infantum
Leishmaniasis, Visceral - blood
Leishmaniasis, Visceral - drug therapy
Leishmaniasis, Visceral - veterinary
Male
Meglumine - administration & dosage
Meglumine - pharmacokinetics
Meglumine - therapeutic use
Meglumine Antimoniate
Metabolic Clearance Rate
Organometallic Compounds - administration & dosage
Organometallic Compounds - pharmacokinetics
Organometallic Compounds - therapeutic use
Pharmacokinetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pharmacokinetics of meglumine antimoniate in dogs with experimentally induced leishmaniosis has been investigated. After infection, dogs received a dose of 75 mg kg −1 of meglumine antimoniate twice daily by subcutaneous injection for 10 days. Blood samples were collected throughout the treatment. No statistical differences were found in the kinetic behaviour of the drug administered as a single dose to healthy dogs and that administered as a multiple dose to infected animals. However, peak plasma concentrations ( C max) of 30.8±12.8 μg ml −1 found after this dosage regimen were higher than those observed after the single dose administration of 100 mg kg −1 24 h −1. Furthermore, sustained antimony concentrations of 1.14±0.52 μg Sb ml −1 were detected throughout the treatment. No signs of toxicity were found in the animals treated indicating that this regimen would be very appropriate to treat canine leishmaniosis.
ISSN:0304-4017
1873-2550
DOI:10.1016/S0304-4017(97)00193-3